Tumor News and Research

RSS
Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

PCF funds two new Young Investigators in China to lead research projects on prostate cancer

PCF funds two new Young Investigators in China to lead research projects on prostate cancer

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Transgenomic launches new mutation detection test for patients with metastatic colorectal cancer

Transgenomic launches new mutation detection test for patients with metastatic colorectal cancer

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Idelalisib phase 1 clinical trial shows positive results in patients with CLL

Study underscores new paradigm in cancer therapy

Study underscores new paradigm in cancer therapy

Secure cloud-based computing system to access, analyze human genomic cancer information

Secure cloud-based computing system to access, analyze human genomic cancer information

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Novel drug may increase the effectiveness of radiation therapy for brain cancer

Novel drug may increase the effectiveness of radiation therapy for brain cancer

Tokai Pharmaceuticals raises $35.5M in Series E financing

Tokai Pharmaceuticals raises $35.5M in Series E financing

Sterling Insurance increases availability of Sterling Critical Condition to 31 states

Sterling Insurance increases availability of Sterling Critical Condition to 31 states

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

UAB genetics and breast cancer experts respond to Angelina Jolie's preventive mastectomy

UAB genetics and breast cancer experts respond to Angelina Jolie's preventive mastectomy

UIC's Center for Clinical and Translational Science selects six research projects for new pilot grants

UIC's Center for Clinical and Translational Science selects six research projects for new pilot grants

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Cancers physically alter cells in lymphatic system to promote the spread of disease

Cancers physically alter cells in lymphatic system to promote the spread of disease

Researchers unravel a mystery about how pancreatic tumor cells feed themselves

Researchers unravel a mystery about how pancreatic tumor cells feed themselves

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.